Research progress in Ph-like childhood acute lymphoblastic leukemia.
- Author:
Xue TANG
1
;
Xia GUO
Author Information
1. Department of Pediatrics, West China Second University Hospital, Sichuan University/Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu 610041, China. guoxkl@163.com.
- Publication Type:Journal Article
- MeSH:
Humans;
Janus Kinase 2;
genetics;
PAX5 Transcription Factor;
genetics;
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;
diagnosis;
drug therapy;
genetics;
Proto-Oncogene Proteins c-abl;
genetics
- From:
Chinese Journal of Contemporary Pediatrics
2017;19(11):1213-1218
- CountryChina
- Language:Chinese
-
Abstract:
Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a subtype of B-lineage ALL (B-ALL) that displays a gene expression profile (GEP) similar to Philadelphia chromosome-positive ALL (PhALL). It has a diverse range of genetic alterations that activate cytokine receptor genes and kinase signaling pathways, frequently accompanied by abnormal transcription factors related to lymphatic development. Children with Ph-like ALL account for 15% of children with high-risk B-ALL. It has adverse clinical features and a poor prognosis. Tyrosine kinase inhibitors combined with chemotherapy can significantly improve the prognosis of children with PhALL, suggesting that targeted therapy based on the molecular cytogenetic abnormalities of Ph-like ALL has good research prospects. This paper expounds the genetic alterations, pathogenesis, clinical features, diagnostic measures, and potential therapeutic approaches of Ph-like childhood ALL based on recent research progress in Ph-like ALL.
